Frontiers in Immunology (Oct 2021)

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens

  • Arianna Draghi,
  • Christopher Aled Chamberlain,
  • Shawez Khan,
  • Krisztian Papp,
  • Martin Lauss,
  • Martin Lauss,
  • Samuele Soraggi,
  • Haja Dominike Radic,
  • Mario Presti,
  • Katja Harbst,
  • Katja Harbst,
  • Aishwarya Gokuldass,
  • Anders Kverneland,
  • Morten Nielsen,
  • Marie Christine Wulff Westergaard,
  • Mads Hald Andersen,
  • Istvan Csabai,
  • Göran Jönsson,
  • Göran Jönsson,
  • Zoltan Szallasi,
  • Inge Marie Svane,
  • Marco Donia

DOI
https://doi.org/10.3389/fimmu.2021.705422
Journal volume & issue
Vol. 12

Abstract

Read online

Detecting the entire repertoire of tumor-specific reactive tumor-infiltrating lymphocytes (TILs) is essential for investigating their immunological functions in the tumor microenvironment. Current in vitro assays identifying tumor-specific functional activation measure the upregulation of surface molecules, de novo production of antitumor cytokines, or mobilization of cytotoxic granules following recognition of tumor-antigens, yet there is no widely adopted standard method. Here we established an enhanced, yet simple, method for identifying simultaneously CD8+ and CD4+ tumor-specific reactive TILs in vitro, using a combination of widely known and available flow cytometry assays. By combining the detection of intracellular CD137 and de novo production of TNF and IFNγ after recognition of naturally-presented tumor antigens, we demonstrate that a larger fraction of tumor-specific and reactive CD8+ TILs can be detected in vitro compared to commonly used assays. This assay revealed multiple polyfunctionality-based clusters of both CD4+ and CD8+ tumor-specific reactive TILs. In situ, the combined detection of TNFRSF9, TNF, and IFNG identified most of the tumor-specific reactive TIL repertoire. In conclusion, we describe a straightforward method for efficient identification of the tumor-specific reactive TIL repertoire in vitro, which can be rapidly adopted in most cancer immunology laboratories.

Keywords